Adamax

Adamax is a synthetic heptapeptide derived from semax; the specific amino acid sequence being Ac-MEHFPG-AG-NH₂

 

 

SKU: 198802 Gulu:
Gawani chikondi chanu

Adamax is a synthetic heptapeptide derived from sanamve; the specific amino acid sequence being Ac-MEHFPG-AG-NH₂.

Semax itself, a fragment of mahomoni adrenocorticotropic (ACTH), possesses potent neurotrophic and cognitive-enhancing properties.

Structural limitations within semax lead to significant limitations to its half-life and efficiency of crossing the blood-brain barrier.

To alleviate these limitations scientists introduced a bulky adamantylacetate group through covalent bonding at the carboxyl terminus.

This modification significantly improved the pharmacokinetic properties of the peptide molecule.

Introduction of this moiety provides near complete resistance to subsequent enzymatic degradation; retention time of the active form of adamax within the body is greatly prolonged.

More excitingly, the previously mentioned ‘ingenious’ design promotes an increase in efficiency with which the peptide crosses said barrier, and enhanced specificity and selectivity is achieved.

Compromising no biological activity, all known effects of semax are either maintained or enhanced.

Kutsatizana

Ac-MEHFPGP-Adam-NH2

Nambala ya CAS

/

Molecular Formula

C50H68N10O12S

Kulemera kwa Maselo

1033.212

Research Of Adamax:

1.Therapeutic Efficacy and Clinical Potential

Clinical trials have shown Adamax to outperform Semax in promoting the growth and protection of ubongo wotengedwa neurotrophic factor (Mtengo wa BDNF) ndi ku mfundo nerve growth factor (NGF).

Replacing Semax as a therapeutic agent, particularly for psychiatric disorders or social cognition enhancement, is a very real possibility.

2.Cognitive Enhancement (Intelligence being a subset)

Direct stimulation of BDNF upregulation is Adamax’s primary function.

Neuronal cell activity, new neuron generation/differentiation and all associated synaptic improvements are what the research is currently focused on.

Hippocampal and prefrontal cortex activity is also increased.

Long term experimental groups have and will continue to show, quantifiably, superior memory and learning abilities.

3.Zotsatira za Neuroprotective

Adamax’s cognitive enhancement and intelligence-boosting functions originate not only from its direct promotion of neural cell growth, but also from demonstrable neuroprotective properties.

Effective reduction of cerebral infarction areas in stroke patients has been demonstrated; stimulation and subsequent recovery of various necrotic cells is another key aspect of this neuroprotection.

Kuchepetsa excitotoxicity and providing near-constant antioxidant effects are additional, well-documented activities.

Positioning itself within this realm, Adamax holds much promise as a true therapeutic agent for neurodegenerative disorders – Alzheimer’s being the prime example, Parkinson’s following closely behind.

4.Stress and Anxiety Relief

Adamax enhances the human ability to adapt to environmental changes; the brain itself must rapidly adjust to, and resist, a variety of physiological stressors resulting from these quick environmental shifts.

Maintaining some form of homeostasis is the end goal.

Modulation of the hypothalamic-pituitary-adrenal (HPA) olamulira is central to this process, increasing or decreasing the appropriate release of neurotransmitters, all lesser ‘stress responses’ being suppressed.

Anxiolytic effects are a primary benefit – drowsiness and cognitive impairment (the near universal side effects of traditional anxiolytics) are completely avoided.

Enhancing cognitive function during any form of anxiety relief is what makes Adamax particularly alluring to researchers and patients alike.

COA

Mtengo wa HPLC

MS

(1)Mtengo, N. V.; Sokolov, O. Y.; Gabaeva, M. V.; Grivennikov, Ine. A.; Andreeva, L. A.; Myasoedov, N. F.; Zozulya, A. A. Semax and Selank Inhibit the Enkephalin-Degrading Enzymes of Human Serum. Russian Journal of Bioorganic Chemistry 2001, 27(3), 156-159. DOI: 10.1023/a:1011373002885.

(2)Vlasova, Ine. M.; Buravtcov, D. E.; Saletsky, A. M. Kuwunika kwa luminescence kwa zigawo zamagazi mu maphunziro a neuroprotective katundu wa mankhwala "Semax" mu cerebral ischemia.. Journal of Applied Spectroscopy 2009, 76(1), 121-126. DOI: 10.1007/s10812-009-9141-y.

(3)Abraham, M. H.; Acree, W. E.; Liu, X. Descriptors for adamantane and some of its derivatives. Journal of Molecular Liquids 2021, 325. DOI: 10.1016/j.molliq.2020.114894.

(4)Dane, C.; Montgomery, A. P.; Kassiou, M. The adamantane scaffold: Beyond a lipophilic moiety. European Journal of Medicinal Chemistry 2025, 291. DOI: 10.1016/j.ejmech.2025.117592.

(5)Dmitrieva, V. G.; Povarova, O. V.; Skvortsova, V. Ine.; Limborska, S. A.; Myasoedov, N. F.; Dergunova, L. V. Semax ndi Pro-Gly-Pro Yambitsani Kulemba kwa Neurotrophins ndi Mitundu Yawo Yolandila Pambuyo pa Cerebral Ischemia. Mafoni ndi Molecular Neurobiology 2009, 30(1), 71-79. DOI: 10.1007/s10571-009-9432-0.

(6)Eremin, K. O.; Kudrin, V. S.; Saransari, P.; Zogulitsa, S. S.; Grivennikov, Ine. A.; Myasoedov, N. F.; Rayevsky, K. S. Osamvera, Chithunzi cha ACTH(4-10) Analogue ndi Nootropic Properties, Imayambitsa Dopaminergic ndi Serotoninergic Brain Systems mu Makoswe. Kafukufuku wa Neurochemical 2005, 30(12), 1493-1500. DOI: 10.1007/s11064-005-8826-8.

(7)Glazova, N. Y.; Manchenko, D. M.; Volodina, M. A.; Merchieva, S. A.; Andreeva, L. A.; Kudrin, V. S.; Myasoedov, N. F.; Levitskaya, N. G. Osamvera, zopangidwa ACTH(4-10) analogue, imachepetsa kusinthika kwamakhalidwe ndi ma neurochemical pambuyo pakukula kwa fluvoxamine mu makoswe oyera. Neuropeptides 2021, 86. DOI: 10.1016/j.npep.2020.102114.

(8)Medvedeva, E. V.; Dmitrieva, V. G.; Limborska, S. A.; Myasoedov, N. F.; Dergunova, L. V. Osamvera, analogue ya ACTH(4−7), imayang'anira kuwonetsa kwa majini oyankha chitetezo chamthupi panthawi yakuvulala kwa ubongo wa ischemic mu makoswe. Molecular Genetics ndi Genomics 2017, 292(3), 635-653. DOI: 10.1007/s00438-017-1297-1.

(9)Pa, C.-U. Kutheka Kwachire kwa "Semax" pa Kukhumudwa. Zithunzi za CNS 2014, 13(1), 20-21. DOI: 10.1017/s1092852900016102.

Kutsatizana:

Ac-MEHFPGP-Adam-NH2

CAS:

N/A

M.W:

1033.21g/mol

Kunyumba Sakani Whatsapp Ntchito Zogulitsa